As we recently demonstrated that intravenous injections of an siRNA targeting an oncogenic lncRNA thymopoietin antisense transcript 1 (TMPO-AS1) efficiently suppressed the xenograft tumor growth and lung metastasis derived from breast cancer cells [46], the therapeutic efficacy of siOIN1 can be evaluated in similar ovarian cancer xenograft models or patient-derived cancer models. This evidence concerns the gene TMPO and breast carcinoma.